AI-Powered Pancreatic Cancer Research

Pancreatic cancer has the lowest survival rate of all major cancers. AI agents research stromal-targeting strategies, KRAS inhibitors, and immunotherapy combinations.

Get a $99 personalized brief on Pancreatic Cancer

14 specialist agents compile a 30–50 page brief from PubMed-indexed research, delivered in 48 hours. Refund + free re-brief if not useful.

Standard of Care

FOLFIRINOX, gemcitabine/nab-paclitaxel, surgical resection (Whipple) for eligible patients.

Prevalence

~64,000 new diagnoses per year in the US. 5th leading cause of cancer death.

Five-Year Survival

Stage IV: ~3%. All stages combined: ~12%.

Key Mutations

KRAS (>90%)
TP53
CDKN2A
SMAD4
BRCA1/2

Key Pathways

kras-mapk
tgf-beta-signaling
hedgehog-signaling

Clinical Trial Focus

KRAS G12D inhibitors, stromal disruption agents, mRNA vaccines (personalized neoantigen), oncolytic viruses.